Skip to content

Author

Jonathan T. Yang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Phase 1a clinical trial of XRD-0394, a first-in-class dual ATM/DNA-PK inhibitor, in combination with palliative radiotherapy.

PURPOSE XRD-0394 is a dual ATM/DNA-PK inhibitor designed to increase tumor radiosensitivity. We evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single-dose XRD-0394 administered with palliative radiotherapy (RT) in a first-in-human trial. PATIENTS AND METHODS In an open-label, multicenter ph...

Christopher T. Chen, M. Gensheimer, Tona M. Gilmer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.